
    
      This study assessed different formulations of the modified formulation of VRVg (VRVg 2-
      formulations 1 [low], 2 [medium] and 3 [high]) tested in parallel to the initial VRVg
      formulation (VRVg-1) and Imovax Rabies. Immune responses were assessed at Day 14, Day 28, Day
      42, and at Month 7. Safety events were also reported.
    
  